Core Insights - Innovent Biologics has successfully closed a global strategic collaboration with Takeda, aimed at accelerating the development and commercialization of next-generation immuno-oncology and antibody-drug conjugate therapies [1][2][3] Financial Details - Takeda will make an upfront payment of US$1.2 billion, which includes a US$100 million equity investment in Innovent at a premium price of HK$112.56 per share [3] - The total deal value could reach up to US$11.4 billion, including potential milestone payments of approximately US$10.2 billion for the development and sales of IBI363, IBI343, and IBI3001 [3] Collaboration Structure - Innovent and Takeda will co-develop IBI363 globally and co-commercialize it in the U.S., with Takeda leading these efforts [7] - Takeda has been granted exclusive commercialization rights for IBI363 outside Greater China and the U.S., along with global manufacturing rights for IBI363 outside Greater China [7] - Takeda also holds exclusive global rights to develop, manufacture, and commercialize IBI343 outside Greater China, and has an option to license global rights for IBI3001 [7] Company Background - Innovent Biologics is a leading biopharmaceutical company founded in 2011, focusing on affordable, high-quality biopharmaceuticals targeting various diseases [5] - The company has launched 17 products and has multiple assets in various stages of clinical trials, partnering with over 30 global healthcare companies [5]
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies